Production (Stage)
Relmada Therapeutics, Inc.
RLMD
$0.7085
-$0.0415-5.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -22.39% | -31.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.49% | -17.09% | |||
| Operating Income | 4.49% | 17.09% | |||
| Income Before Tax | 5.88% | 14.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.88% | 14.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.88% | 14.13% | |||
| EBIT | 4.49% | 17.09% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 6.61% | 14.13% | |||
| Normalized Basic EPS | 4.25% | 16.83% | |||
| EPS Diluted | 6.61% | 14.13% | |||
| Normalized Diluted EPS | 4.25% | 16.83% | |||
| Average Basic Shares Outstanding | 0.78% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.78% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||